Hirohito Metoki, MD

home / authors / hirohito-metoki-md

Articles

White-coat hypertension and progression to home hypertension

Takashi Ugajin, MS;Atsushi Hozawa, MD, PhD;Takayoshi Ohkubo, MD, PhD;Kei Asayama, MD;Masahiro Kikuya, MD, PhD;Taku Obara, MS;Hirohito Metoki, MD;Haruhisa Hoshi, MD, PhD;Junichiro Hashimoto, MD

September 24th 2008

Our study aimed to clarify whether white-coat hypertension represents a transient state in the development of hypertension outside medical settings. We followed up 128 subjects with white-coat hypertension and compared their risk of progression to home hypertension with that of 649 sustained normotensive subjects. After 8 years of follow-up, subjects with white-coat hypertension had an approximately 3-fold higher risk of eventually manifesting home hypertension. We concluded that patients with white-coat hypertension should be carefully monitored.

Prognosis of "masked" hypertension vs. "white-coat" hypertension

Takayoshi Ohkubo, MD, PhD;Masahiro Kikuya, MD, PhD;Hirohito Metoki, MD;Kei Asayama, MD;Taku Obara, MS;Junichiro Hashimoto, MD, PhD;Kazuhito Totsune, MD, PhD;Haruhisa Hoshi, MD, PhD;Hiroshi Sat

September 22nd 2008

We compared the prognosis of patients with "white-coat" hypertension (WCHT) with that of patients with "masked" hypertension (MHT). The 10-year composite risk of stroke morbidity and cardiovascular mortality for patients with WCHT was similar to the risk for patients with sustained normal blood pressure, whereas the risk was markedly increased for patients with MHT and sustained hypertension. This indicates that conventional blood pressure measurements may fail to distinguish some patients at high or low risk.